Personalized Cancer Care. Realized.

Forging a Clearer Path to Cancer Treatments

Covid-19 Updates: Stenoparib has shown to block replication of the SARS-CoV-2 human coronavirus in vitro. Allarity Therapeutics hold the commercial rights to stenoparib. 

Allarity Therapeutics is a clinical-stage precision medicine company actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. The company is leveraging its proprietary, highly accurate Drug Response Predictor (DRP®) technology to refine patient selection and improve clinical outcomes. Publicly traded on the NASDAQ First North, Allarity (ALLR: SS) is headquartered in Horsholm, Denmark, with US operations, and is committed to enhancing patient outcomes through improved decision-making and personalized cancer care.

Our Pipeline

Allarity’s robust pipeline includes six anti-cancer drugs that address significant cancer markets. All programs include a DRP® companion diagnostic to select patients most likely to respond to treatment.

Our Platform

Our DRP® Technology is a first-in-class, highly validated diagnostic platform that models human tumor biology and can help predict whether a cancer patient will respond or not to a particular drug

Publications

Results from our DRP® platform have been published in numerous peer-reviewed scientific journals, highlighting the predictive capabilities of our proprietary approach to precision medicine.

Events

Sedermeradagen

Date: 28/09/2020
Time: 11:00am
Location: Clarion Malmö Live, Dag Hammarskjölds Torg 2, Malmö, Sweden/

Q1 2020 Conference Call

Date: 29/05/2020
Time: 5:00pm CST
Location: Online

The DRP® Platform

No two people are the same. Neither are their cancers. DRP® technology is a unique and best-in-class proprietary diagnostic platform built upon a deep systems biology analysis of all transcriptional (RNA) changes in tumor cells in response to a broad range of drug types, and refined with actual gene expression data from more than 3,000 patient tumors
Play Video

"We are building a personalized medicine company developing new therapeutics for unmet needs in the treatment of human cancers through use of our world-class companion diagnostics platform."

Steve Carchedi, CEO

Allarity Leadership Steve Carchedi

Oncology Venture is now

Allarity Therapeutics

At Allarity Therapeutics, we are defining a bright future for patients in a new paradigm of precision cancer treatments. Our mission is to bring clarity to personalized oncology medicines, marrying innovative therapies and superior companion diagnostics, to help fully realize the promise of personalized cancer care.

Allarity Therapeutics Logo